Tiny Vergent seals modest Series B in pursuit of cancer imaging agent
A biotech with only two full-time employees now has millions of more dollars to spend in its work on an imaging molecule.
Based out of Minneapolis, MN, Vergent Bioscience announced Tuesday morning that investors handed the company $21.5 million via a Series B round. The last time the company got funding was in 2018, thanks to a Series A worth $8.7 million.
The biotech’s emphasis is in a molecule called VGT-309, a fluorescent imaging agent that would allow surgeons to more quickly find solid tumors in patients during surgery. The biotech had originally in-licensed the molecule from Stanford. CEO and president John Santini tells Endpoints News that initially, Vergent was looking at dyes for non-human use only, for R&D applications.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.